Expertise in
4
conditions

Dr. Jane Raymond

Oncology
Allegheny General Hospital
320 E North Ave, 
Pittsburgh, PA 
Expertise in
4
conditions
Allegheny General Hospital
320 E North Ave, 
Pittsburgh, PA 

Overview

Jane Raymond is an Oncologist practicing medicine in Pittsburgh, Pennsylvania.

Dr. Raymond is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Inflammatory Breast Cancer, Breast Cancer, Angiosarcoma, and Paget Disease of the Breast.

She is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 4 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in PA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Allegheny General Hospital
320 E North Ave, Pittsburgh, PA 15212
Other Locations
West Penn Hosp Outpatient SVCS Allegheny
314 E North Ave, Pittsburgh, PA 15212

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: May 29, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
EndoPredict® Extended Endocrine Trial (EXET): A Prospective Registry to Evaluate the Impact of EndoPredict® Test on Extended Endocrine Treatment Decisions and Patient Outcomes.
EndoPredict® Extended Endocrine Trial (EXET): A Prospective Registry to Evaluate the Impact of EndoPredict® Test on Extended Endocrine Treatment Decisions and Patient Outcomes.
Enrollment Status: Terminated
Publish Date: May 17, 2022
Intervention Type: Other
The ACTS Intervention to Reduce Breast Cancer Treatment Disparity
The ACTS Intervention to Reduce Breast Cancer Treatment Disparity
Enrollment Status: Completed
Publish Date: August 31, 2018
Intervention Type: Behavioral
Study Phase: Not Applicable
View 3 Less Clinical Trials

2 Total Publications

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609).
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609).
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 14, 2021
Similar Doctors
Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

Allegheny General Hospital

320 E North Ave, 
Pittsburgh, PA 
 (0.1 miles away)
412-359-6391
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nathan Bahary is an Oncologist practicing medicine in Pittsburgh, Pennsylvania. Dr. Bahary is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

UPMC Presbyterian

200 Lothrop St, 
Pittsburgh, PA 
 (2.5 miles away)
412-383-1370
Languages Spoken:
English
See accepted insurances

Jason Luke is an Oncologist practicing medicine in Pittsburgh, Pennsylvania. Dr. Luke is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Melanoma, Metastatic Uveal Melanoma, Uveal Melanoma, Melanoma of the Eye, and Liver Embolization.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Office

5150 Centre Ave, 
Pittsburgh, PA 
 (3.3 miles away)
412-692-4724
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Leonard Appleman is an Oncologist practicing medicine in Pittsburgh, Pennsylvania. Dr. Appleman is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, and WT1-Related Wilms Tumor Syndromes.

Frequently Asked Questions about Dr. Jane Raymond

How do I make an appointment with Dr. Jane Raymond?

You can book an appointment with Dr. Jane Raymond by calling their office at 412-359-6147. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jane Raymond a top-rated expert for Inflammatory Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jane Raymond is classified as an Distinguished expert for Inflammatory Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jane Raymond specialize in?

While Dr. Jane Raymond is a Oncology, they have specific expertise in Inflammatory Breast Cancer, Breast Cancer, and Angiosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Jane Raymond participate in research or clinical trials?

Yes. Dr. Jane Raymond has published 2 articles and abstracts on conditions like Inflammatory Breast Cancer. You can view a list of Dr. Jane Raymond's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jane Raymond accept my insurance?

Dr. Jane Raymond accepts most major insurance plans, including Humana. We recommend calling the office directly at 412-359-6147 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Raymond's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile